New Pfizer Data In Lung Cancer, Ewing's Sarcoma, Prostate Cancer And Other Difficult-to-treat Tumor Types To Be Presented At ASC

NEW YORK -- Pfizer announced today that study results across several difficult-to-treat cancers will be presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3, 2008. Pfizer will hold two briefings for journalists on June 1 and investors on June 2. Researchers will present the latest data from the breadth of Pfizer's oncology portfolio, focused in four areas of discovery: anti-angiogenesis, signal transduction, immuno-oncology and cytotoxics/potentiators. Metastatic Renal Cell Carcinoma (mRCC) -- Updated overall survival data from a Phase 3 trial evaluating single-agent, oral SUTENT(R) (sunitinib malate) versus interferon-alfa (IFN-(alpha)) in the first-line...